Brainstorm Cell Therapeutics, Inc. (BCLI)
1.168
+0.10
(+9.62%)
USD |
OTCM |
Sep 01, 16:00
Brainstorm Cell Therapeutics Research and Development Expense (Annual) : 3.976M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 3.976M |
| December 31, 2024 | 4.411M |
| December 31, 2023 | 10.48M |
| December 31, 2022 | 13.67M |
| December 31, 2021 | 14.98M |
| December 31, 2020 | 22.33M |
| December 31, 2019 | 17.20M |
| December 31, 2018 | 8.293M |
| December 31, 2017 | 0.977M |
| December 31, 2016 | 2.25M |
| December 31, 2015 | 4.949M |
| December 31, 2014 | 4.772M |
| December 31, 2013 | 2.917M |
| Date | Value |
|---|---|
| December 31, 2012 | 1.77M |
| December 31, 2011 | 1.689M |
| December 31, 2010 | 1.045M |
| December 31, 2009 | 0.181M |
| December 31, 2008 | 1.639M |
| December 31, 2007 | 1.925M |
| December 31, 2006 | 0.9892M |
| March 31, 2005 | 16.35M |
| March 31, 2004 | 0.00 |
| March 31, 2003 | 0.00 |
| March 31, 2002 | 0.00 |
| March 31, 2001 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| NovelStem International Corp. | -- |
| Summit Therapeutics, Inc. | 537.67M |
| Kezar Life Sciences, Inc. | 33.76M |
| Protara Therapeutics, Inc. | 42.49M |
| Clene, Inc. | 12.66M |